BIIB BIOGEN INC.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 875045 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY2.3%
TTM net income YoY-78.4%
TTM EPS YoY-78.9%
Revenue 3-yr CAGR1.0%
Net income 3-yr CAGR-38.1%
Margins
Gross margin74.0%
Operating margin—
Net margin3.4%
FCF margin20.1%
EBITDA margin—
Returns
ROE1.9%
ROA1.1%
ROIC (approx.)—
Asset turnover0.34x
Leverage & solvency
Liabilities / assets41.0%
Debt / equity0.39x
Current ratio1.95x
Interest coverage—
Cash quality & payout
Operating cash flow / net income6.47x
Accruals ratio-6.2%
Payout ratio—
Capex / revenue1.7%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $2.80B | $2.74B | $2.48B | $2.28B | $2.53B | $2.65B | $2.43B | $2.45B |
| Cost of revenue | $748.40M | $776.90M | $661.00M | $495.50M | $674.40M | $605.00M | $629.30M | $583.50M |
| Gross profit | $2.06B | $1.96B | $1.82B | $1.78B | $1.86B | $2.04B | $1.80B | $1.87B |
| R&D expense | $574.00M | $529.60M | $539.00M | $509.40M | $436.10M | $399.00M | $434.10M | $513.30M |
| SG&A expense | $752.00M | $709.70M | $607.30M | $682.50M | $594.80M | $583.80M | $572.50M | $680.00M |
| Interest expense | $87.50M | $82.30M | $67.60M | $67.50M | $67.40M | $72.60M | $60.00M | $60.00M |
| Pretax income | -$9.00M | $132.40M | $377.70M | -$56.00M | $557.30M | $744.00M | $311.20M | $291.50M |
| Income tax | $11.60M | $34.90M | $58.20M | -$7.10M | $90.80M | $109.20M | $70.70M | $24.80M |
| Net income | -$20.60M | $97.50M | $319.50M | -$48.90M | $466.50M | $634.80M | $240.50M | $266.70M |
| EPS (basic) | -0.14 | 0.66 | 2.17 | — | 3.18 | 4.33 | 1.65 | — |
| EPS (diluted) | -0.14 | 0.66 | 2.15 | — | 3.17 | 4.33 | 1.64 | — |
| Weighted avg. shares (diluted) | 147.80M | 148.70M | 148.40M | — | 147.10M | 146.70M | 146.60M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $1.30B | $1.28B | $3.38B | $3.01B | $3.86B | $2.76B | $2.60B | $2.38B |
| Short-term investments | $0 | $0 | $900.00M | $807.20M | $97.60M | — | — | $0 |
| Receivables | — | — | — | $1.34B | — | — | — | $1.40B |
| Inventory | $2.22B | $2.38B | $1.95B | $2.17B | $2.21B | $2.27B | $2.27B | $2.46B |
| Current assets | $7.58B | $7.31B | $9.19B | $8.97B | $8.94B | $7.97B | $7.63B | $7.46B |
| PP&E, net | $2.97B | $2.99B | $3.02B | $3.06B | $3.08B | $3.10B | $3.13B | $3.18B |
| Goodwill | $6.99B | $6.99B | $6.49B | $6.49B | $6.49B | $6.49B | $6.48B | $6.48B |
| Intangibles | $13.38B | $13.52B | $9.05B | $9.18B | $9.33B | $9.47B | $9.58B | $9.69B |
| Total assets | $32.05B | $32.09B | $29.48B | $29.44B | $29.21B | $28.33B | $28.03B | $28.05B |
| Current liabilities | $3.90B | $3.92B | $3.00B | $3.35B | $3.29B | $3.18B | $5.30B | $5.53B |
| Short-term debt | — | — | — | $0 | — | — | — | $1.75B |
| Long-term debt | $7.29B | $7.29B | $6.29B | $6.29B | $6.29B | $6.28B | $4.55B | $4.55B |
| Total debt | $7.29B | $7.29B | $6.29B | $6.29B | $6.29B | $6.28B | $4.55B | $6.30B |
| Total liabilities | $13.13B | $13.24B | $10.83B | $11.18B | $11.00B | $10.70B | $11.05B | $11.33B |
| Shareholders' equity | $18.92B | $18.85B | $18.65B | $18.26B | $18.21B | $17.63B | $16.98B | $16.72B |
| Net debt | $5.99B | $6.01B | $2.91B | $3.28B | $2.42B | $3.52B | $1.95B | $3.92B |
| Shares outstanding | — | — | — | 146.80M | — | — | — | 145.80M |
| Cash flow statement | ||||||||
| Operating cash flow | $640.80M | $448.90M | $645.50M | $511.90M | $1.27B | $160.90M | $259.30M | $760.90M |
| Capital expenditure | $40.40M | $40.90M | $51.20M | $43.90M | $46.20M | $26.60M | $37.10M | $39.30M |
| Free cash flow | $600.40M | $408.00M | $594.30M | $468.00M | $1.23B | $134.30M | $222.20M | $721.60M |
| Investing cash flow | -$222.10M | -$3.84B | -$209.50M | -$1.23B | -$35.10M | -$57.00M | -$47.30M | -$18.60M |
| Financing cash flow | -$393.80M | $1.30B | -$43.80M | -$137.00M | -$130.20M | -$11.70M | -$23.00M | $7.90M |
| Depreciation & amortization | $68.30M | $67.90M | $204.40M | $200.20M | $66.50M | $66.90M | $183.20M | $184.00M |
| Stock-based compensation | $81.50M | $77.40M | $84.00M | $59.60M | $75.30M | $74.90M | $81.00M | $75.10M |
Free plan shows the latest 8 periods; Pro shows all 74 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.